MED19 and prostate cancer: However, the ratio of canonical MED19 to alternative MED19 mRNA expression is higher in early-stage primary cancers, including prostate, whereas the ratio of alternative MED19 versus canonical MED19 is higher in later-stage prostate cancer metastasis.